These innovative molecules represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://graysonwgte756842.dm-blog.com/39239822/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide